In this prospective process, patients with acute urticaria who were referred to Razi, Loghman, and Shohadaye Tajrish hospitals in 1392 are studied. Inclusion criteria are age between 10 and 70 years old, negative history of autoimmune or immunodeficiency diseases, negative history of any specific drugs and willingness to participate in the study. Also, patients who received antihistaminic drugs or combination of corticosteroids a month before the trial, pregnant women, and patients with previous allergy to antihistamines or any ingredients in the herbal medicinal products will be excluded from the study. All patients will be informed about the project process and benefits and side effects of the drugs and the informed consent in order to participate in the project will be obtained.Then, patients will be divided into 2 groups, randomly. In the first group, plantago major aqueous extract in form of syrup will be administered twice a day and in the second group cetirizine syrup will be administered in the same way (Cetirizine is recommended as the first line of the second-generation antihistamine drugs in the treatment protocol of urticaria). A check list will be provided for each patient to document every urticaria lesions which have been experienced during the day. Patients will be examined on days 3 and 15 in person and on days 6 and 9 via phone call. In each check up, the scratching , resistance to therapy, and side effects will be examined. At the end of the treatment, patient's satisfaction will be questioned. The collected data will be analyzed by SPSS software.